Endocrine Testing Market is Expected to Reach USD 2.03 Billion Globally in 2019

According to a new market report published by Transparency Market Research "Endocrine Testing Market (E2, FSH, hCG, LH, DHEAS, Progesterone, Testosterone, TSH, Prolactin, Cortisol, Insulin Tests and Others)- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global endocrine testing market was valued at USD1.53billion in 2012 and is estimated to reach a market worth USD2.03 billion in 2019 growing at a CAGR of 4.3% from 2013 to 2019.

Browse Endocrine Testing Market Report with Full TOC at http://www.transparencymarketresearch.com/endocrine-testing-market.html

Pharmaceuticals.jpg


Endocrine system refers to the collection of endocrine glands (ductless glands) and secretory organs that release hormones directly into the blood stream. Endocrine system is instrumental in regulating certain body mechanisms such as metabolism, growth and sexual development and emotions. Also, it enables the body to cope up with different events such as cellular mechanisms and stress by acting in co-ordination with the nervous system. Hormones refer to the body's chemical messengers and render information and instruction transfer from one set of cells to another. Hormones can act only on those cells that are genetically programmed to receive and respond to the information or instructions released by hormones. There are lot of factors that influence the hormone levels including changes in body fluids and minerals in blood along with stress and infection.

Several endocrine tests are performed to assess varying levels of hormones in the body. This results in the determination of hypersecretion (excess) or hyposecretion (less) that consequently helps in early diagnosis and treatment of several endocrine disorders (such as sexual dysfunction, diabetes and others). Consistent rise in diabetic, obese and infertile patient population across the globe has broadened the scope for growth and acceptance of various endocrine test kits. In addition, introduction of technologically advanced diagnostic platforms coupled with growing healthcare awareness and surge in preference for quick and easy operating test platforms have further augmented the growth prospects for endocrine test kits or methodologies. On the contrary, high development costs and less flexible reimbursement policies are some of the factors that may hamper the growth of global endocrine testing market.

Endocrine tests are instrumental in monitoring the normal and abnormal levels of hormones secreted in the body. The market for insulin tests is estimated to record highest growth rate during the forecast period majorly due to increasing incidence of the diabetes worldwide coupled with technological advances and increasing healthcare awareness across the globe. As per International Diabetes Federation (IDF), in the year 2013, around 382 million people suffered from diabetes and are anticipated to rise to 592 million by 2035. Also, 80% of the diabetic population lives in low and middle income nations. Thyroid stimulating hormone test constituted the largest market segment owing to increasing thyroid dysfunction cases and pose high risk for acquiring cardiovascular disorders. The increased acceptance of endocrine test kits is attributed to increasing incidence of obesity, unhealthy food habits, physical inactivity and consistent technological advances. Follicle stimulating hormone test followed by human chorionic Gonadotropin test occupied third and fourth position in the market by 2019. Hence, all these factors mentioned above influence the growth and acceptance of several test kits.

Among the diagnostic technology market the tandem mass spectrometry segment is estimated to record highest growth rate due to high specificity and accuracy rendered by this platform in determination of hormone levels. Immunoassays and sensor technologies are expected to be the other fastest growing diagnostic technology segments during the forecast period owing to their increased use in several endocrine testing methodologies. However, high cost involved in the research and development along with subsequent commercialization of the same results in the high costs of the tests thereby hampering the growth of the market.

While, the ambulatory care centers of the total market, by end users segment is expected to be the fastest growing segment during the forecast period due to quick service offerings and costs reduction due to less hospital stay and gain competitive edge over the other end users. In addition, home based tests and commercial laboratories are also expected to grow considerably as compared to others (hospitals and physician offices).

At the regional level, Europe was the largest market in 2012for endocrine testing market followed by North America. The growth has been attributed to the presence of sophisticated laboratories along with increased participation of the respective governments in these regions. Asia-Pacific region represents the fastest growing region during the forecast period from 2013 to 2019.This is majorly due to huge untapped patient population, increasing healthcare awareness and healthcare spending and presence of large number of undiagnosed and untreated patients in low and middle income nations. In addition, rise in disposable incomes and increased investments of many key players in these emerging economies will further boost the growth and development in this region. For instance, Abbott Laboratories has been investing heavily in the emerging economies such as India and China to enhance their revenues to 50% by 2015. The company has opened around six manufacturing and R&D facilities in Asia-Pacific region. This substantiates the lucrative business opportunities in these regions and enables the companies to introduce and commercialize quality endocrine tests thereby enhancing the strength of the market players.

Related & Recently Published Reports by Transparency Market Research

Orthopedic Devices Market (Hip, Knee, Spine, Shoulder, Elbow, Foot and Ankle, Craniomaxillofacial and Other Extremities) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

http://www.transparencymarketresearch.com/orthopedic-devices-market.html


Orthopedic devices have been used successfully in restoring mobility, reducing pain and improving quality of life of millions of people across the globe. The success can be easily illustrated by the dominance of orthopedic devices. The orthopedic devices market has been extensively analyzed on the basis of factors such as the technology used, success rate, reimbursement coverage and geographical reach.

This report studies the global orthopedic devices market from the perspective of various anatomical locations in the human body. The market is thus broadly segmented into hip, knee, shoulder, elbow, foot and ankle, spine, cranio-maxillofacial and other extremities. These anatomical locations are further categorized into joint implants, internal fixation devices and external fixation devices, based on the availability of the products in the market. Geographically, the orthopedic devices market is analyzed for four major regions, namely North America, Europe, Asia and Rest of the World (RoW).

Each of the segments in the orthopedic devices market has been analyzed on the basis of its current and future market size for the period 2011 to 2019, in terms of revenue generation in USD million, considering 2011 and 2012 as the base years. The compounded annual growth rate (%CAGR) for each segment of orthopedic devices market have been provided for the forecast period 2013 to 2019 along with the estimations of market size.




The endocrine testing market is characterized by the presence of well-established as well as new players solely operating in this market. The major companies competing in this market are Agilent Technologies, F.Hoffmann La-Roche, Ltd., Abbott Laboratories and Siemens Healthcare and DiaSorin S.p.A.

The Global endocrine testing market is segmented as follows:

Endocrine Testing Market, by Test

Estradiol (E2) Test

Follicle Stimulating Hormone (FSH) Test

Human Chorionic Gonadotropin (hCG) Test

Luteinizing Hormone (LH) Test

Dehydroepiandrosterone sulfate (DHEAS) Test

Progesterone Test

Testosterone Test

Thyroid Stimulating Hormone (TSH) Test

Prolactin Test

Cortisol Test

Insulin Test

Others (Gastrin, Thymosin, Secretin, etc.)

Endocrine Testing Market, by Diagnostic Technologies

Tandem Mass Spectrometry

Immunoassay Technologies

Monoclonal and Polyclonal Antibody Technologies

Sensor Technologies

Clinical Chemistry Technologies

Others

Endocrine Testing Market, by End Users

Hospitals

Commercial Laboratories

Ambulatory Care Centers

Home Based Tests

Physician Offices

Endocrine Testing Market, by Geography

North America

Europe

Asia-Pacific

Rest of the World (RoW)


Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
blog_import_5321851a8b2bf.jpg

Blogs :
http://globalmarketresearchreports.quora.com/

https://udallas.academia.edu/transparencymarketresearch

http://globalmarketresearchreports.wordpress.com/

http://seekingalpha.com/user/16370542/instablog



Table of Content

Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.3.1 Sources
1.3.1.1 Secondary Research
1.3.1.2 Primary Research
1.3.1.3 Models
1.3.1.4 Assumptions
1.4 List of Abbreviations

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Endocrine Testing Market (2012 & 2019)
2.2 Global Endocrine Testing Market, by Test, 2012 (USD Million)
2.3 Global Endocrine Testing Market, by Diagnostic Technologies, 2012 (USD Million)

Chapter 3 Market Overview
3.1 Overview
3.1.1 Introduction to Elements of Endocrine System
3.1.2 Market Potential of Endocrine Testing Market
3.1.3 Future Scenario of Endocrine Testing Market
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 Increasing Incidence of diabetic and obese population worldwide
3.2.1.2 Consistent rise in geriatric population Worldwide
3.2.1.3 Technological advancements
3.2.2 Market Restraints
3.2.2.1 High cost of technology
3.2.2.2 Lack of healthcare awareness in emerging economies
3.2.3 Market Opportunity
3.2.3.1 Investment opportunity
3.3 Porter’s Five Force Analysis for the Global Endocrine Testing Market
3.3.1 Bargaining power of suppliers
3.3.2 Bargaining power of buyers
3.3.3 Threat of substitutes
3.3.4 Threat of new entrants
3.3.5 Competitive rivalry
3.1 Market Attractiveness Analysis: Global Endocrine Technologies Market, by Geography

Chapter 4 Endocrine Testing Market, by Test
4.1 Overview
4.1.1 Global Endocrine Testing Market, by Test, 2011 – 2019 (USD Million)
4.2 Estradiol (E2) Test
4.2.1 Global Estradiol (E2) Test Market, 2011 – 2019 (USD Million)
4.3 Follicle Stimulating Hormone (FSH) Test
4.3.1 Global Follicle Stimulating Hormone (FSH) Test Market, 2011 – 2019 (USD Million)
4.4 Human Chorionic Gonadotropin (hCG) Test
4.4.1 Global Human Chorionic Gonadotropin (hCG) Test Market, 2011 – 2019 (USD Million)
4.5 Luteinizing Hormone (LH) Test
4.5.1 Global Luteinizing Hormone (LH) Test Market, 2011 – 2019 (USD Million)
4.6 Dehydroepiandrosterone Sulfate (DHEAS) Test
4.6.1 Global Dehydroepiandrosterone Sulfate (DHEAS) Test Market, 2011 – 2019 (USD Million)
4.7 Progesterone Test
4.7.1 Global Progesterone Test Market, 2011 – 2019 (USD Million)
4.8 Testosterone Test
4.8.1 Global Testosterone Test Market, 2011 – 2019 (USD Million)
4.9 Thyroid Stimulating Hormone (TSH) Test
4.9.1 Global Thyroid Stimulating Hormone (TSH) Test Market, 2011 – 2019 (USD Million)
4.10 Prolactin Test
4.10.1 Global Prolactin Test Market, 2011 – 2019 (USD Million)
4.11 Cortisol Test
4.11.1 Global Cortisol Test Market, 2011 – 2019 (USD Million)
4.12 Insulin Test
4.12.1 Global Insulin Test Market, 2011 – 2019 (USD Million)
4.13 Others
4.13.1 Global Others Market, 2011 – 2019 (USD Million)

Chapter 5 Endocrine Testing Market, by Diagnostic Technologies
5.1 Overview
5.1.1 Global Endocrine Testing Market, by Diagnostic Technologies 2011 – 2019 (USD Million)
5.2 Tandem Mass Spectrometry
5.2.1 Global Tandem Mass Spectrometry Market, 2011 – 2019 (USD Million)
5.3 Immunoassay (Enzyme Linked Assays(EIA), Radio Immunoassay (RIA))Technologies
5.3.1 Global Immunoassay Technologies Market, 2011 – 2019 (USD Million)
5.4 Monoclonal and Polyclonal Antibody Technologies
5.4.1 Global Monoclonal and Polyclonal Antibody Technologies Market, 2011 – 2019 (USD Million)
5.5 Sensor Technologies
5.5.1 Global Sensor Technologies Market, 2011 – 2019 (USD Million)
5.6 Clinical Chemistry Technologies
5.6.1 Global Clinical Chemistry Technologies Market, 2011 – 2019 (USD Million)
5.7 Others ((Liquid Chromatography + Tandem Mass Spectrometry (LC-MS/MS), High performance Liquid Chromatography (HPLC), etc.)
5.7.1 Global Others Market, 2011 – 2019 (USD Million)

Chapter 6 Endocrine Testing Market, by End Users
6.1 Overview
6.1.1 Global Endocrine Testing Market, by End Users 2011 – 2019 (USD Million)
6.2 Hospitals
6.2.1 Global Hospitals Market, 2011 – 2019 (USD Million)
6.3 Commercial Laboratories
6.3.1 Global Commercial Laboratories Market, 2011 – 2019 (USD Million)
6.4 Ambulatory Care Centers
6.4.1 Global Ambulatory Care Centers Market, 2011 – 2019 (USD Million)
6.5 Home Based Tests
6.5.1 Global Home Based Tests Market, 2011 – 2019 (USD Million)
6.6 Physician Offices
6.6.1 Global Physician Offices Market, 2011 – 2019 (USD Million)

Chapter 7 Endocrine Testing Market, by Geography

7.1 Overview
7.1.1 Global Endocrine Testing Market, by Geography 2011 – 2019 (USD Million)
7.2 North America
7.2.1 North America Endocrine Testing Market, 2011 – 2019 (USD Million)
7.3 Europe
7.3.1 Europe Endocrine Testing Market, 2011 – 2019 (USD Million)
7.4 Asia-Pacific
7.4.1 Asia-Pacific Endocrine Testing Market, 2011 – 2019 (USD Million)
7.5 Rest of the World (RoW)
7.5.1 RoW Endocrine Testing Market, 2011 – 2019 (USD Million)

Chapter 8 Competitive Landscape
8.1 Market Share by Key Players: Global Endocrine Testing Market, 2012 (%)
8.1.1 Global Endocrine Testing Market Share Analysis, by Key Players, 2012 (%)

Chapter 9 Recommendations
9.1 Market strategies for success
9.2 Barriers to be considered

Chapter 10 Company Profiles
10.1 Abbott Laboratories
10.1.1 Company Overview
10.1.2 Financial Overview
10.1.3 Product Portfolio
10.1.4 Business Strategies
10.1.5 Recent Developments
10.2 AB SCIEX LLC
10.2.1 Company Overview
10.2.2 Financial Overview
10.2.3 Product Portfolio
10.2.4 Business Strategies
10.2.5 Recent Developments
10.3 Agilent Technologies
10.3.1 Company Overview
10.3.2 Financial Overview
10.3.3 Product Portfolio
10.3.4 Business Strategies
10.3.5 Recent Developments
10.4 Biomedical Diagnostics
10.4.1 Company Overview
10.4.2 Financial Overview
10.4.3 Product Portfolio
10.4.4 Business Strategies
10.4.5 Recent Developments
10.5 bioMerieux
10.5.1 Company Overview
10.5.2 Financial Overview
10.5.3 Product Portfolio
10.5.4 Business Strategies
10.5.5 Recent Developments
10.6 Bio-Rad Laboratories, Inc.
10.6.1 Company Overview
10.6.2 Financial Overview
10.6.3 Product Portfolio
10.6.4 Business Strategies
10.6.5 Recent Developments
10.7 DiaSorin S.p.A
10.7.1 Company Overview
10.7.2 Financial Overview
10.7.3 Product Portfolio
10.7.4 Business Strategies
10.7.5 Recent Developments
10.8 F. Hoffmann-La Roche Ltd.
10.8.1 Company Overview
10.8.2 Financial Overview
10.8.3 Product Portfolio
10.8.4 Business Strategies
10.8.5 Recent Developments
10.9 Laboratory Corporation of America Holdings (LabCorp)
10.9.1 Company Overview
10.9.2 Financial Overview
10.9.3 Product Portfolio
10.9.4 Business Strategies
10.9.5 Recent Developments
10.10 Ortho Clinical Diagnostics
10.10.1 Company Overview
10.10.2 Financial Overview
10.10.3 Product Portfolio
10.10.4 Business Strategies
10.10.5 Recent Developments
10.11 Quest Diagnostics
10.11.1 Company Overview
10.11.2 Financial Overview
10.11.3 Product Portfolio
10.11.4 Business Strategies
10.11.5 Recent Developments
10.12 Siemens Healthcare
10.12.1 Company Overview
10.12.2 Financial Overview
10.12.3 Product Portfolio
10.12.4 Business Strategies
10.12.5 Recent Developments
10.13 Sysmex Corporation
10.13.1 Company Overview
10.13.2 Financial Overview
10.13.3 Product Portfolio
10.13.4 Business Strategies
10.13.5 Recent Developments
10.14 Thermo Fisher Scientific
10.14.1 Company Overview
10.14.2 Financial Overview
10.14.3 Product Portfolio
10.14.4 Business Strategies
10.14.5 Recent Developments


Contact us :

Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Topic : Health
Genre : Mental/Health

Post a comment

Private comment

Profile

marketsize

Author:marketsize
I am Research Analyst And Business Development Manager At Transparency Market Research

Visit http://www.transparencymarketresearch.com/

Latest journals
Monthly archive
Category
Search form
Link
Friend request form

Want to be friends with this user.

QR code
QR